Celcuity Inc., a clinical-stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's drug candidate includes Gedatolisib, which selectively targets various Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic targets of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2 to treat patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) or HR+/HER2-, advanced or metastatic breast cancer (ABC), and patients with metastatic castration resistant prostate cancer (mCRPC). It also engages in developing CELsignia diagnostic platform. The company had a license agreement with Pfizer Inc. for the development and commercialization rights to Gedatolisib. Celcuity Inc. was founded in 2011 and is based in Minneapolis, Minnesota.

Celcuity Inc.

The latest announcement is out from Celcuity ( ($CELC) ). On June 3, 2026, Celcuity Inc. entered into an underwriting agreement for a public offeri...

Celcuity Refinances Debt with New Convertible Notes Offering

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Travere Therapeutics (TVTX), Gilead Sciences (GILD) ...

Analysts Offer Insights on Healthcare Companies: Travere Therapeutics (TVTX), Gilead Sciences (GILD) and Celcuity (CELC)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Disc Medicine (IRON) and Celcuity (CELC) with bullis...

Analysts Offer Insights on Healthcare Companies: Disc Medicine (IRON) and Celcuity (CELC)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Labcorp Holdings (LH), Moderna (MRNA) and Celcuity...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	CELC	$87.76	-0.33%	2.13M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	CELC	$87.76	-0.3%	2.13M
3
4
5
6

CELC

CELC

No Data Available

Get Celcuity Inc. Data in Excel

Get Celcuity Inc. Data in Excel